

# Syngene

Ref: Syn/CS/SE/Reg 30/2023-24/Dec/10

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 &  
3, Bommasandra Industrial Area, IV  
Phase, Jigani Link Road, Bengaluru  
560 099, Karnataka, India  
T +91 80 6891 8000  
F +91 80 6775 8808  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

December 23, 2023

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Subject: Update on the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd**

This update follows our previous communications on July 4, 2023, and December 1, 2023, regarding the acquisition of the biologics manufacturing facility from Stelis Biopharma Ltd for a gross consideration of Rs. 617 Crores and a net consideration of Rs. 563.2 Crores post adjustments. The Company has completed a payment of Rs. 158.2 Crores on December 22, 2023 in addition to the initial payment of Rs. 395 Crores made on December 1, 2023. The balance Rs. 10 Crores are being withheld by the Company, to be released post the fulfilment of additional conditions by Stelis Biopharma Limited.

Request you to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Priyadarshini Mahapatra  
Company Secretary and Compliance Officer